Lahontan Drills 12.2m Grading 1.25 g/t Au Oxide at Calvada East

Lahontan Gold Corp. reported additional 2026 RC drill results at its Santa Fe Mine project. Seven holes totaling 1,990m were drilled at Calvada East, Slab West, and a deep geophysical test. Highlights include CAL26-12R: 12.2m at 1.26 g/t Au Eq oxide, and CAL26-11R: 13.7m at 1.10 g/t Au Eq in Tertiary volcanic rocks.

Original reporting
Published Aug 5, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lahontan Drills 12.2m Grading 1.25 g/t Au Oxide at Calvada East — source image
Decision brief

The 30-second read

$LGCXFBullishMed
01

Why it matters

The disclosed intercepts at Calvada East and Slab West strengthen the geological case for oxide gold mineralization and a new Summit Fault exploration target, which can increase expectations for a future resource estimate update.

02

Market read

This is a junior explorer catalyst driven by specific drill intercept grades and lengths, likely to move sentiment and trading activity in the near term while awaiting further assay results and an updated MRE/PEA.

03

What to watch

The release is RC drilling with estimated true thickness (80-100% of drilled interval) and Au Eq assumptions; traders may discount impact until assay density, metallurgical recovery, and an updated MRE/PEA are published.

Relevance 6/10Novelty 6/10Timing: pre-market today (Aug. 5, 2026) drill results headline catalyst

Background

Lahontan is restarting and advancing the Santa Fe Mine project in Nevada, targeting a return to production in 2027, and is running a 2026 drilling program to update resources and economics.

Company-level read

Ticker impact

$LGCXFBullishMedium confidence
Context

Lahontan Gold reported new RC drill intercepts at Santa Fe, including 12.2m grading 1.25 g/t Au oxide and 13.7m grading 1.01 g/t Au Eq in Tertiary volcanic rocks.

Expected impact

Near-term sentiment likely positive for LGCHF/LGCXF on increased perceived resource conversion probability, but magnitude may be limited given microcap liquidity and lack of updated resource/PEA numbers.

Evidence & confidence

The article discloses specific, higher-grade intercepts and frames them as first significant mineralization in Tertiary volcanic rocks, which can drive speculative re-rating. However, it does not provide updated resource estimates, economics, or financing details, limiting decisiveness.

Market effects

Adds incremental positive signal for Nevada Walker Lane gold exploration, but impact is likely confined to the company and small-cap gold sentiment rather than the broader sector.

Reinforces investor interest in Nevada gold projects, with potential spillover to peers only if follow-on drilling expands the discovery.

Low global relevance; this is a single-project exploration update without macro or cross-market linkage.

Counterpoint

High-grade intercepts may not translate into resource growth if continuity, true thickness, and grade distribution do not hold up in follow-up drilling.

Key entities

  • Lahontan Gold Corp.

    Reported additional 2026 RC drill results at the Santa Fe Mine Project, including higher-grade oxide gold intercepts and a new exploration target along the Summit Fault.

  • Santa Fe Mine Project

    Nevada gold and silver project where the company is conducting drilling to expand and upgrade resources and support a future PEA.

Related articles

$VNRXMed

VolitionRx reports clinical progress across diagnostic platform

VolitionRx (VNRX) reported progress in its Nu.Q diagnostic platform, with high sensitivity and specificity in detecting cancers. Its Nu.Q NETs test is part of a €6.3M French program. The company saw a 134% revenue increase, reduced operating losses, and is in licensing discussions. It also expanded a supply agreement with Fujifilm Vet Systems for a feline cancer test.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$NSRXMed

Nasus Pharma presents phase 2 data on intranasal epinephrine

Nasus Pharma (NYSE:NSRX) presented Phase 2 study data for NS002, an intranasal epinephrine powder, showing faster therapeutic threshold reach than autoinjectors. No serious adverse events were reported. The company plans a pivotal study by late 2026, with results expected in Q1 2027. NS002 is being developed as a needle-free alternative for anaphylaxis treatment.